title: Predictive value of liver enzymes and inflammatory biomarkers for the severity of liver fibrosis stage in HIV/HCV co-infected patients.
abstract: OBJECTIVE
  The aim of our study was to assess a possible association between plasma inflammatory biomarkers (CRP, IL-6, soluble CD14) and the extent of fibrosis or cirrhosis using a FibroScan® in HIV/HCV co-infected patients.
  
  
  METHODS
  This cross-sectional study assessed 60 HIV/HCV co-infected patients who had paired plasma samples and FibroScan® values available. All included patients were controlled for HIV infection (HIV-1 RNA <50 copies/mL) and had detectable HCV RNA levels. Levels of three biomarkers were measured in all samples using commercial ELISA kits. Multivariate logistic regression models identified factors associated with the METAVIR stages of fibrosis (F0-F2 vs. F3-F4).
  
  
  RESULTS
  In univariate logistic regression analyses, in addition to sCD14 (odds ratio [OR] = 3.23, 95% confidence interval [95%CI] = 1.30-7.97, P = 0.01), aspartate aminotransferase (AST), alanine aminotransferase, platelet counts, and CD4 cell counts were associated with the stage of liver fibrosis and, thus, were introduced into the model. However, only AST (OR = 1.06, 95%CI = 1.02-1.10, P = 0.0009) was independently associated with F3-F4 stage liver fibrosis.
  
  
  CONCLUSIONS
  In our study of HIV/HCV co-infected patients, sCD14 plasma level, a biomarker of monocyte activation, was not independently associated with the F3-F4 stage of liver fibrosis. We hypothesize that the higher levels of inflammation markers observed in HIV/HCV co-infected patients, compared to HCV mono-infected patients, prevent this association being observed within this population.
authors.affiliation: Laboratoire de Virologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Groupe Hospitalier Bichat-Claude Bernard, HUPNVS, Université Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, EA4409, Paris, France. charlotte.charpentier@bch.aphp.fr
authors.forename: Charlotte
authors.initials: C
authors.lastname: Charpentier
authors.forename: Karen
authors.initials: K
authors.lastname: Champenois
authors.forename: Anne
authors.initials: A
authors.lastname: Gervais
authors.forename: Roland
authors.initials: R
authors.lastname: Landman
authors.forename: Véronique
authors.initials: V
authors.lastname: Joly
authors.forename: Sylvie
authors.initials: S
authors.lastname: Le Gac
authors.forename: Lucile
authors.initials: L
authors.lastname: Larrouy
authors.forename: Florence
authors.initials: F
authors.lastname: Damond
authors.forename: Françoise
authors.initials: F
authors.lastname: Brun-Vézinet
authors.forename: Diane
authors.initials: D
authors.lastname: Descamps
authors.forename: Yazdan
authors.initials: Y
authors.lastname: Yazdanpanah
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood*; D002097:C-Reactive Protein; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D060085:Coinfection / Q000150:complications*; D003430:Cross-Sectional Studies; D004797:Enzyme-Linked Immunosorbent Assay; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D015850:Interleukin-6; D018950:Lipopolysaccharide Receptors; D008103:Liver Cirrhosis / Q000097:blood / Q000175:diagnosis* / Q000201:enzymology / Q000209:etiology*; D016015:Logistic Models
chemical_list: D015415:Biomarkers; D015850:Interleukin-6; D018950:Lipopolysaccharide Receptors; D002097:C-Reactive Protein; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase